Clinical trial

Biological Effects of Quercetin in COPD Phase II

NCT06003270

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-11-01

PhasePHASE2

Study timeline

Study start (actual)2023-11-01Date precision: day

Registry last updated2024-04-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Obstructive Pulmonary Diseaseunresolved

Emphysemaunresolved

Chronic Bronchitis With Airway Obstructionunresolved

Interventions

Quercetin 1000 mgDRUG

Quercetin 500 MGDRUG · verified · RxNorm: quercetin 500 MG

Sponsors & collaborators

Temple Universitylead sponsor

National Center for Complementary and Integrative Health (NCCIH)collaborator

Quercegen Pharmaceuticalscollaborator

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06003270 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.